Page 66 - 2020_01-Haematologica-web

B. Dholaria et al.
allybeusedinthesettingofaclinicaltrial.
• The administration of manipulated DLI after T-cell
depleted or T-cell replete haploidentical transplantation, such as allodepleted or gene-modified T cells, should only be performed in the setting of a clinical trial.
• Patients should be monitored closely with frequent disease-specific MRD testing and donor-chimerism after DLI administration.
• Mismatched-HLA allele loss was detected in one-
third of leukemia relapses after a haplo-HCT. Such patients are unlikely to benefit from DLI from the original donor. A second allo-HCT from a related donor with a different mismatched haplotype or a mismatched unrelat- ed donor may be considered if HLA-loss is confirmed.
Acknowledgments
The authors would like to thank Vidya B. Pai, MD, for assis- tance with proofreading.
References
1. Bejanyan N, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow trans- plant research study. Biol Blood Marrow Transplant. 2015;21(3):454-459.
2. D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2018.
3. Ciurea SO, Labopin M, Socie G, et al. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer. 2018;124(10):2134-2141.
4. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
5. Pati AR, Godder K, Lamb L, et al. Immunotherapy with donor leukocyte infu- sions for patients with relapsed acute myeloid leukemia following partially mis- matched related donor bone marrow trans- plantation. Bone Marrow Transplant. 1995; 15(6):979-981.
6. Sica S, Di Mario A, Salutari P, et al. Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treat- ment of relapse after allogeneic bone mar- row transplantation. Bone Marrow Transplant. 1995;16(3):483-485.
7. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malig- nancies after stem cell transplantation revis- ited. Cancer Treat Rev. 2010;36(7):528-538.
8. Chalandon Y, Passweg JR, Schmid C, et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2010;45(3):558-564.
9. Takami A, Yano S, Yokoyama H, et al. Donor lymphocyte infusion for the treat- ment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11): 1785-1790.
10. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic
stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(31): 4938-4945.
11. Jedlickova Z, Schmid C, Koenecke C, et al. Long-term results of adjuvant donor lym- phocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(5):663-667.
12. Haines HL, Bleesing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant dis- eases. Biol Blood Marrow Transplant. 2015;21(2):288-292.
13. Liga M, Triantafyllou E, Tiniakou M, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regi- men. Biol Blood Marrow Transplant. 2013;19(1):75-81.
14. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51(6):786-792.
15. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10-24.
16. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell deple- tion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38(4):291-297.
17. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of out- comes for patients in remission at transplan- tation. Blood. 2008;112(9):3574-3581.
18. Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alpha- beta T-cell and B-cell depletion. Blood. 2017;130(5):677-685.
19. Lang PJ, Schlegel PG, Meisel R, et al. Safety and Efficacy of Tcralpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Prospective Multicenter Phase I/II Clinical Trial. Blood. 2017;130(Suppl 1):214.
20. Roy DC, Lachance S, Cohen S, et al. Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-
versus-host disease (GVHD) in the absence of GVHD prophylaxis. Br J Haematol. 2019;186(5):754-766.
21. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-ran- domised phase I-II study. Lancet Oncol. 2009;10(5):489-500.
22. Zhou X, Dotti G, Krance RA, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after hap- loidentical stem cell transplantation. Blood. 2015;125(26):4103-4113.
23. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttrans- plant cyclophosphamide vs matched unre- lated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033-1040.
24. Bashey A, Zhang X, Jackson K, et al. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post- Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA- Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. Biol Blood Marrow Transplant. 2016;22(1):125- 133.
25. McCurdy SR, Kasamon YL, Kanakry CG, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017; 102(2):391-400.
26. Solomon SR, Sizemore CA, Zhang X, et al. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. Biol Blood Marrow Transplant. 2016;22(10): 1816-1822.
27. Wang Y, Liu DH, Xu LP, et al. Superior graft- versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic com- parison. Biol Blood Marrow Transplant. 2011;17(6):821-830.
28. Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infu- sions for patients with relapsed hematologic malignancies after related HLA-haploidenti- cal bone marrow transplantation. Biol Blood Marrow Transplant. 2014;20(3):314-318.
29. Ghiso A, Raiola AM, Gualandi F, et al. DLI after haploidentical BMT with post-trans- plant CY. Bone Marrow Transplant. 2015;50(1):56-61.
30. Goldsmith SR, Slade M, DiPersio JF, et al. Donor-lymphocyte infusion following hap- loidentical hematopoietic cell transplanta-
56
haematologica | 2020; 105(1)